TYROSINE KINASE INHIBITORS Russian patent published in 2011 - IPC C07D221/16 C07D409/04 C07D401/04 C07D401/14 C07D401/12 C07D405/14 C07D417/04 C07D417/14 C07D471/04 A61K31/435 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula I: or its pharmaceutically acceptable salt or stereoisomer, where a is independently equal to 0 or 1; b is independently equal to 0 or 1; R¹ is selected from aryl, heterocyclyl and NR¹⁰R¹¹; said aryl or heterocyclyl group is optionally substituted with between one and five substitutes, each independently selected from R⁸; R⁵ is selected from C_1-6alkyl, C_2-6alkenyl, -C(=O)NR¹⁰R¹¹, NHS(O)₂NR¹⁰R¹¹ and NR¹⁰R¹¹, each alkyl, alkenyl or aryl is optionally substituted with between one and five substitutes, each independently selected from R⁸; R⁸ independently denotes (C=O)_aO_bC₁-C₁₀alkyl, (C=O)_aO_baryl, (C=O)_aO_bheterocyclyl, OH, O_a(C=O)_bNR¹⁰R¹¹ or (C=O)_aC_bC₃-C₈cycloalkyl, said alkyl, aryl, heterocyclyl are optionally substituted with one, two or three substitutes selected from R⁹; R⁹ is independently selected from (C=O)_aC_b(C₁-C₁₀)alkyl and N(R^b)₂; R¹⁰ and R¹¹ is independently selected from H, (C=O)C_b(C₁-C₁₀)alkyl, C₁-C₁₀alkyl, SO₂R^a, said alkyl is optionally substituted with one, two or three substitutes selected from R⁸ or R¹⁰ and R¹¹ can be taken together with nitrogen to which they are bonded with formation of a monocyclic heterocycle with 5 members in each ring and optionally contains one or two heteroatoms, in addition to the nitrogen, selected from N and S, said monocyclic heterocycle is optionally substituted with one, two or three substitutes selected from R⁹; R^a is independently selected from (C₁-C₆)alkyl, (C₂-C₆)alkenyl; and R^b is independently selected from H, (C₁-C₆)alkyd, as well as to a pharmaceutical composition for inhibiting receptor tyrosine kinase MET based on this compound, as well as a method of using said compound to produce a drug.

EFFECT: novel compounds which can be used to treat cell proliferative diseases, disorders associated with MET activity and for inhibiting receptor tyrosine kinase MET are obtained and described.

8 cl, 32 ex, 4 tbl